ORYZON to present further REIMAGINE efficacy data with vafidemstat at the 7th World Congress on ADHD in Lisbon
MADRID, SPAIN and CAMBRIDGE MA.
• Complete data on the adult Attention Deficit Hyperactivity disorder cohort will be presented
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company will present the efficacy results from the adult Attention Deficit Hyperactivity disorder (ADHD) cohort from the REIMAGINE Phase IIa trial at the 7th World Congress on ADHD, which will be held April 25-28 in Lisbon (Portugal). The aggregated results from the ADHD cohort plus the Borderline Personality Disorder (BPD) cohort will also be presented. Positive efficacy data from the BPD cohort were recently published at the 27th European Congress of Psychiatry (EPA 2019) in Warsaw (Poland) earlier this month.